Ivana K. Kim, MD

Ivana K. Kim, MD, is a full-time clinician scientist in the Retina Service at Mass. Eye and Ear, an Associate Professor of Ophthalmology with Harvard Medical School, and the Evangelos S. Gragoudas Distinguished Scholar in Retina.

Clinical Interests

Diseases and surgery of the retina and vitreous, diabetic retinopathy, macular degeneration, retinal detachment

Research Interests

Macular degeneration, ocular angiogenesis, molecular genetics of uveal melanoma

Publications

For a full publication list, please see her CV. A representative list (2006 - 2012) is available through www.pubmed.gov.

Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology. 2011 Jan; 118(1): 111-8.

Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, Kiss S, Flaxel C, Collins M, Miller J, Hauswirth W, Maclachlan T, Wadsworth S, Scaria A. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther. 2011 Feb; 19(2): 260-5.

CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19; 364 (20): 1897-908.

Feehan M, Hartman J, Durante R, Morrison MA, Miller JW, Kim IK, DeAngelis MM. Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics. BMC Med Genet. 2011 Jun 17; 12: 83.

Chen L, Miller JW, Vavvas D, Kim IK. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration. Retina. 2011 Nov; 31(10): 2078-83.

Page updated: January 25, 2013